Indeed, here we show that interactions of leukemic murine and human cells with the BMM via the fibronectin/integrin β3/integrin-linked kinase (ILK)-mediated signaling pathway influence leukemia progression and clinical outcome in BCR-ABL1T315I+ imatinib-resistant CML in vivo. Here, ILK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.